Dithiaarsanes induce oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase

Journal of Medicinal Chemistry

Volumn 57, Issue 12, 2014, Pages 5203-5211

  Liu, Yaping ^a   Duan, Dongzhu ^a   Yao, Juan ^a   Zhang, Baoxin ^a   Peng, Shoujiao ^a   Ma, Huilong ^a   Song, Yanlin ^a   Fang, Jianguo ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4-AMINOPHENYL) 1,3,2 DITHIARSINANE; ARSENIC DERIVATIVE; CASPASE 3; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HL 60 CELL LINE; HUMAN; HUMAN CELL; OXIDATIVE STRESS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; HL-60 CELLS; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SULFHYDRYL COMPOUNDS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84903512710     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500221p     Document Type: Article

References (67)

1. Beauchamp, E. M.; Uren, A. A new era for an ancient drug: arsenic trioxide and hedgehog signaling Vitam. Horm. 2012, 88, 333-354
2. Evens, A. M.; Tallman, M. S.; Gartenhaus, R. B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future Leuk. Res. 2004, 28, 891-900
3. Waxman, S.; Anderson, K. C. History of the development of arsenic derivatives in cancer therapy Oncologist 2001, 6, 3-10
4. Zhang, T. D. Treatment of acute granulocytic leukemia with "Ai Ling No. 1"-clinical analysis and experimental research Zhongxiyi Jiehe Zazhi 1984, 4, 19-20
5. Zhang, T. D.; Chen, G. Q.; Wang, Z. G.; Wang, Z. Y.; Chen, S. J.; Chen, Z. Arsenic trioxide, a therapeutic agent for APL Oncogene 2001, 20, 7146-7153
6. Miodragovic, E. U.; Quentzel, J. A.; Kurutz, J. W.; Stern, C. L.; Ahn, R. W.; Kandela, I.; Mazar, A.; O'Halloran, T. V. Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes Angew. Chem., Int. Ed. 2013, 52, 10749-10752
7. Chen, H.; Pazicni, S.; Krett, N. L.; Ahn, R. W.; Penner-Hahn, J. E.; Rosen, S. T.; O'Halloran, T. V. Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment Angew. Chem., Int. Ed. 2009, 48, 9295-9299
8. Dilda, P. J.; Hogg, P. J. Arsenical-based cancer drugs Cancer Treat. Rev. 2007, 33, 542-564
9. Swindell, E. P.; Hankins, P. L.; Chen, H.; Miodragovic, D. U.; O'Halloran, T. V. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes Inorg. Chem. 2013, 52, 12292-12304
10. Arner, E. S.; Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase Eur. J. Biochem. 2000, 267, 6102-6109
11. Lu, J.; Holmgren, A. Thioredoxin system in cell death progression Antioxid. Redox Signaling 2012, 17, 1738-1747
12. Rigobello, M. P.; Bindoli, A. Mitochondrial thioredoxin reductase purification, inhibitor studies, and role in cell signaling Methods Enzymol. 2010, 474, 109-122
13. Arner, E. S. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions Biochim. Biophys. Acta 2009, 1790, 495-526
14. Laurent, T. C.; Moore, E. C.; Reichard, P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B J. Biol. Chem. 1964, 239, 3436-3444
15. Chae, H. Z.; Chung, S. J.; Rhee, S. G. Thioredoxin-dependent peroxide reductase from yeast J. Biol. Chem. 1994, 269, 27670-27678
16. Brot, N.; Weissbach, L.; Werth, J.; Weissbach, H. Enzymatic reduction of protein-bound methionine sulfoxide Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 2155-2158
17. Gonzalez Porque, P.; Baldesten, A.; Reichard, P. The involvement of the thioredoxin system in the reduction of methionine sulfoxide and sulfate J. Biol. Chem. 1970, 245, 2371-2374
18. Powis, G.; Kirkpatrick, D. L. Thioredoxin signaling as a target for cancer therapy Curr. Opin. Pharmacol. 2007, 7, 392-397
19. Urig, S.; Becker, K. On the potential of thioredoxin reductase inhibitors for cancer therapy Semin. Cancer Biol. 2006, 16, 452-465
20. Biaglow, J. E.; Miller, R. A. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy Cancer. Biol. Ther. 2005, 4, 6-13
21. Cai, W.; Zhang, L.; Song, Y.; Wang, B.; Zhang, B.; Cui, X.; Hu, G.; Liu, Y.; Wu, J.; Fang, J. Small molecule inhibitors of mammalian thioredoxin reductase Free Radical Biol. Med. 2012, 52, 257-265
22. Sun, R. W.; Lok, C. N.; Fong, T. T.; Li, C. K.; Yang, Z. F.; Zou, T.; Siu, A. F.; Che, C. M. A dinuclear cyclometalated gold(III)-phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo Chem. Sci. 2013, 4, 1979-1988
23. Oehninger, L.; Kuster, L. N.; Schmidt, C.; Munoz-Castro, A.; Prokop, A.; Ott, I. A chemical-biological evaluation of rhodium(I) N-heterocyclic carbene complexes as prospective anticancer drugs Chem.-Eur. J. 2013, 19, 17871-17880
24. Millet, R.; Urig, S.; Jacob, J.; Amtmann, E.; Moulinoux, J. P.; Gromer, S.; Becker, K.; Davioud-Charvet, E. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors J. Med. Chem. 2005, 48, 7024-7039
25. Klossowski, S.; Muchowicz, A.; Firczuk, M.; Swiech, M.; Redzej, A.; Golab, J.; Ostaszewski, R. Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system J. Med. Chem. 2012, 55, 55-67
26. Shen, S.; Li, X. F.; Cullen, W. R.; Weinfeld, M.; Le, X. C. Arsenic binding to proteins Chem. Rev. 2013, 113, 7769-7792
27. Sapra, A.; Thorpe, C. An arsenical-maleimide for the generation of new targeted biochemical reagents J. Am. Chem. Soc. 2013, 135, 2415-2418
28. Park, D.; Don, A. S.; Massamiri, T.; Karwa, A.; Warner, B.; MacDonald, J.; Hemenway, C.; Naik, A.; Kuan, K. T.; Dilda, P. J.; Wong, J. W.; Camphausen, K.; Chinen, L.; Dyszlewski, M.; Hogg, P. J. Noninvasive imaging of cell death using an Hsp90 ligand J. Am. Chem. Soc. 2011, 133, 2832-2835
29. Huang, C.; Yin, Q.; Zhu, W.; Yang, Y.; Wang, X.; Qian, X.; Xu, Y. Highly selective fluorescent probe for vicinal-dithiol-containing proteins and in situ imaging in living cells Angew. Chem., Int. Ed. 2011, 50, 7551-7556
30. Griffin, B. A.; Adams, S. R.; Tsien, R. Y. Specific covalent labeling of recombinant protein molecules inside live cells Science 1998, 281, 269-272
31. Lu, J.; Chew, E. H.; Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 12288-12293
32. Zhang, L.; Duan, D.; Liu, Y.; Ge, C.; Cui, X.; Sun, J.; Fang, J. Highly selective off-on fluorescent probe for imaging thioredoxin reductase in living cells J. Am. Chem. Soc. 2014, 136, 226-233
33. Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Sun, J.; Ge, C.; Peng, S.; Fang, J. Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase Free Radical Biol. Med. 2014, 69, 15-25
34. Cai, W.; Zhang, B.; Duan, D.; Wu, J.; Fang, J. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells Toxicol. Appl. Pharmacol. 2012, 262, 341-348
35. Cai, W.; Zhang, L.; Song, Y.; Zhang, B.; Cui, X.; Hu, G.; Fang, J. 3,4,4′-Trihydroxy-trans-stilbene, an analogue of resveratrol, is a potent antioxidant and cytotoxic agent Free Radical Res. 2011, 45, 1379-1387
36. Duan, D.; Zhang, B.; Yao, J.; Liu, Y.; Fang, J. Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells Free Radical Biol. Med. 2014, 70, 182-193
37. Loiseau, P. M.; Lubert, P.; Wolf, J. G. Contribution of dithiol ligands to in vitro and in vivo trypanocidal activities of dithiaarsanes and investigation of ligand exchange in an aqueous solution Antimicrob. Agents Chemother. 2000, 44, 2954-2961
38. Stevenson, K. J.; Hale, G.; Perham, R. N. Inhibition of pyruvate dehydrogenase multienzyme complex from Escherichia coli with mono- and bifunctional arsenoxides Biochemistry 1978, 17, 2189-2192
39. Heredia-Moya, J.; Kirk, K. L. An improved synthesis of arsenic-biotin conjugates Bioorg. Med. Chem. 2008, 16, 5743-5746
40. Sundberg, L.; Porath, J. Preparation of adsorbents for biospecific affinity chromatography. I. Attachment of group-containing ligands to insoluble polymers by means of bifuctional oxiranes J. Chromatogr. 1974, 90, 87-98
41. Styblo, M.; Del Razo, L. M.; Vega, L.; Germolec, D. R.; LeCluyse, E. L.; Hamilton, G. A.; Reed, W.; Wang, C.; Cullen, W. R.; Thomas, D. J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells Arch. Toxicol. 2000, 74, 289-299
42. Nakamuro, K.; Sayato, Y. Comparative studies of chromosomal aberration induced by trivalent and pentavalent arsenic Mutat. Res. 1981, 88, 73-80
43. Fang, J.; Lu, J.; Holmgren, A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity J. Biol. Chem. 2005, 280, 25284-25290
44. Arner, E. S.; Bjornstedt, M.; Holmgren, A. 1-Chloro-2,4-dinitrobenzene is an irreversible inhibitor of human thioredoxin reductase. Loss of thioredoxin disulfide reductase activity is accompanied by a large increase in NADPH oxidase activity J. Biol. Chem. 1995, 270, 3479-3482
45. Du, Y.; Zhang, H.; Lu, J.; Holmgren, A. Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose J. Biol. Chem. 2012, 287, 38210-38219
46. Javvadi, P.; Hertan, L.; Kosoff, R.; Datta, T.; Kolev, J.; Mick, R.; Tuttle, S. W.; Koumenis, C. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells Cancer Res. 2010, 70, 1941-1950
47. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
48. Eguchi, R.; Fujimori, Y.; Takeda, H.; Tabata, C.; Ohta, T.; Kuribayashi, K.; Fukuoka, K.; Nakano, T. Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells J. Cell. Physiol. 2011, 226, 762-768
49. Liu, L.; Trimarchi, J. R.; Navarro, P.; Blasco, M. A.; Keefe, D. L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis J. Biol. Chem. 2003, 278, 31998-32004
50. Bode, A.; Dong, Z. Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers Drug Resist. Updates 2000, 3, 21-29
51. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 1996, 88, 1052-1061
52. Budihardjo, I.; Oliver, H.; Lutter, M.; Luo, X.; Wang, X. Biochemical pathways of caspase activation during apoptosis Annu. Rev. Cell Dev. Biol. 1999, 15, 269-290
53. Nordberg, J.; Arner, E. S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radical Biol. Med. 2001, 31, 1287-1312
54. Saitoh, M.; Nishitoh, H.; Fujii, M.; Takeda, K.; Tobiume, K.; Sawada, Y.; Kawabata, M.; Miyazono, K.; Ichijo, H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1 EMBO J. 1998, 17, 2596-2606
55. Mitchell, D. A.; Morton, S. U.; Fernhoff, N. B.; Marletta, M. A. Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 11609-11614
56. Matthews, J. R.; Wakasugi, N.; Virelizier, J. L.; Yodoi, J.; Hay, R. T. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62 Nucleic Acids Res. 1992, 20, 3821-3830
57. Anestal, K.; Prast-Nielsen, S.; Cenas, N.; Arner, E. S. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells PLoS One 2008, 3, e1846
58. Anestal, K.; Arner, E. S. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine J. Biol. Chem. 2003, 278, 15966-15972
59. Oehninger, L.; Kuster, L. N.; Schmidt, C.; Munoz-Castro, A.; Prokop, A.; Ott, I. A chemical-biological evaluation of rhodium(I) N-heterocyclic carbene complexes as prospective anticancer drugs Chem.-Eur. J. 2013, 19, 17871-17880
60. Wang, Y.; Liu, M.; Cao, R.; Zhang, W.; Yin, M.; Xiao, X.; Liu, Q.; Huang, N. A soluble bis-chelated gold(I) diphosphine compound with strong anticancer activity and low toxicity J. Med. Chem. 2013, 56, 1455-1466
61. Koster, S. D.; Alborzinia, H.; Can, S.; Kitanovic, I.; Wolfl, S.; Rubbiani, R.; Ott, I.; Riesterer, P.; Prokop, A.; Merza, K.; Metzler-Nolte, N. A spontaneous gold(I)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line Chem. Sci. 2012, 3, 2062-2072
62. Hickey, J. L.; Ruhayel, R. A.; Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Filipovska, A. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols J. Am. Chem. Soc. 2008, 130, 12570-12571
63. Meyer, A.; Bagowski, C. P.; Kokoschka, M.; Stefanopoulou, M.; Alborzinia, H.; Can, S.; Vlecken, D. H.; Sheldrick, W. S.; Wolfl, S.; Ott, I. On the biological properties of alkynyl phosphine gold(I) complexes Angew. Chem., Int. Ed. 2012, 51, 8895-8899
64. Citta, A.; Schuh, E.; Mohr, F.; Folda, A.; Massimino, M. L.; Bindoli, A.; Casini, A.; Rigobello, M. P. Fluorescent silver(I) and gold(I)-N-heterocyclic carbene complexes with cytotoxic properties: mechanistic insights Metallomics 2013, 5, 1006-1015
65. Craig, S.; Gao, L.; Lee, I.; Gray, T.; Berdis, A. J. Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation J. Med. Chem. 2012, 55, 2437-2451
66. Jan, K. Y.; Wang, T. C.; Ramanathan, B.; Gurr, J. R. Dithiol compounds at low concentrations increase arsenite toxicity Toxicol. Sci. 2006, 90, 432-439
67. Liu, B.; Pan, S.; Dong, X.; Qiao, H.; Jiang, H.; Krissansen, G. W.; Sun, X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice Cancer Sci. 2006, 97, 675-681